What the business is, and whether it's a good one at a fair price.
Manufactures active pharmaceutical ingredients (APIs) for the global animal health and human pharma industries, running 5 production facilities in India with FY26 revenue of Rs.500.95 crore. Animal health APIs account for 95% of Q4 FY26 revenues, supplying 5 of the world's top 10 animal health companies and serving roughly 430 customers across 54-55 countries; exports make up 75% of revenue. The product portfolio has grown from about 20 APIs three years ago to 45 APIs, with a stated target of 9-10 new APIs added annually, and the customer base widened by 47 new accounts in Q4 FY26. Manufacturing capacity is being expanded in two phases at Tarapur: Phase I is operational at 70-80% utilisation, while Phase II commissioning is now slated for early Q2 FY27 with commercial production targeted from H2 FY27; total Phase II capex is Rs.210 crore (Rs.182.75 crore spent), with the new plant expected to generate Rs.350-400 crore of revenue at peak over 3-4 years. Regulated-market access is being built through 5 VMFs filed with the US FDA (6 more planned), 6 CEPs and 9 DMS targeted by end CY2026, with Europe sales starting in CY2026 and US sales from FY28. Raw materials are the largest input cost at 49.3% of revenue, followed by other operating expenses at 24.6% and employee costs at 13.1%.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from NGL FINE CHEM LIMITED's filed financials and exchange disclosures
NGL FINE CHEM LIMITED is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol NGLFINE.
Yes. Over the trailing twelve months NGL FINE CHEM LIMITED reported a net profit of ₹57 Cr on revenue of ₹536 Cr.
Yes. The dividend yield is 0.06% at the current price. It paid out 2% of its profit as dividend in FY26.
No. Debt stands at 0.33× equity, and it carries net debt of ₹106 Cr. That is lower than 28% of its 171 Pharmaceuticals peers.
On trailing P/E, NGL FINE CHEM LIMITED ranks 86 of 169 in Pharmaceuticals — cheaper than 49% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session NGL FINE CHEM LIMITED moves 1.99% — that is the median absolute close-to-close move across its last 268 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by NGL FINE CHEM LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
